Eric T. Gangl
Eric T. Gangl has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
- Aatman S. Doshi
Bioscience, Oncology R&D, AstraZeneca, Waltham, Massachusetts
43 shared publications - Alwin G. Schuller
Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States
43 shared publications - Cecilia Kankkonen
Discovery Sciences, R&D, AstraZeneca, Mölndal, Sweden
43 shared publications - Clare Hoover
AstraZeneca 1 Oncology Targeted Discovery, Early Oncology R&D Waltham, Massachusetts
43 shared publications - David Henry
10Toxicology, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
43 shared publications - Deanna A. Mele
Oncology R&D, AstraZeneca, Waltham, MA, USA
43 shared publications
Latest Publications
- 3 July 2026
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 54 (9) , 100358
Breaking the 1% unbound threshold: An IQ consortium whitepaper on the evaluation of plasma protein binding of highly bound compounds
- 3 July 2026
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 54 (9) , 100358
Breaking the 1% unbound threshold: An IQ consortium whitepaper on the evaluation of plasma protein binding of highly bound compounds
- Open Access
- 20 January 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (2) , e70475
Open‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women
Camizestrant is the next‐generation oral selective estrogen receptor degrader and complete estrogen receptor antagonist in Phase 3 development for hormone receptor‐positive breast cancer. To investigate the impact of manufacturing changes during pivotal Phase 3 studies, this open‐label, randomized crossover study of 32 postmenopausal healthy volunteers determined the relative bioavailability of a tablet used in early clinical studies (Phase 1 tablet), a tablet designed for late‐phase development (prototype Phase 3 tablet), and an oral solution. Absolute oral bioavailability in the fasted state (using a [ 14 C] camizestrant intravenous microtracer) and effects of a high‐fat meal on the prototype Phase 3 tablet were also determined. The geometric mean ratios (GMRs) of the prototype Phase 3/Phase 1 tablets (% [90% CI]) for C max and AUC, respectively were 98.7 (87.4–111.5) and 97.4 (92.6–102.5) at 75 mg ( n = 15), and 96.6 (86.9–107.5) and 100.4 (96.2–104.9) at 300 mg ( n = 15). GMRs of the prototype Phase 3 tablet/oral solution for C max and AUC were 96.2 (85.3–108.7) and 99.5 (94.6–104.6) at 75 mg ( n = 15). Fed‐to‐fasted C max and AUC GMRs were 106.2 (94.3–119.7) ( n = 16) and 109.8 (104.4–115.5) ( n = 15) at 75 mg ( n = 16), and 115.9 (104.3–128.7) and 102.3 (98.0–106.8) at 300 mg ( n = 15). Absolute oral bioavailability at 75 mg ( n = 6) and 300 mg ( n = 6) was 42.5% (36.8%–49.0%) and 55.1% (48.5%–62.5%). The formulations showed similar exposures, supporting the planned manufacturing changes. Camizestrant exhibited moderate bioavailability; exposures were similar under fasted and high‐fat meal conditions, supporting its administration with or without food.
- 20 January 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (2) , e70475
Open AccessOpen‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women
Camizestrant is the next‐generation oral selective estrogen receptor degrader and complete estrogen receptor antagonist in Phase 3 development for hormone receptor‐positive breast cancer. To investigate the impact of manufacturing changes during pivotal Phase 3 studies, this open‐label, randomized crossover study of 32 postmenopausal healthy volunteers determined the relative bioavailability of a tablet used in early clinical studies (Phase 1 tablet), a tablet designed for late‐phase development (prototype Phase 3 tablet), and an oral solution. Absolute oral bioavailability in the fasted state (using a [ 14 C] camizestrant intravenous microtracer) and effects of a high‐fat meal on the prototype Phase 3 tablet were also determined. The geometric mean ratios (GMRs) of the prototype Phase 3/Phase 1 tablets (% [90% CI]) for C max and AUC, respectively were 98.7 (87.4–111.5) and 97.4 (92.6–102.5) at 75 mg ( n = 15), and 96.6 (86.9–107.5) and 100.4 (96.2–104.9) at 300 mg ( n = 15). GMRs of the prototype Phase 3 tablet/oral solution for C max and AUC were 96.2 (85.3–108.7) and 99.5 (94.6–104.6) at 75 mg ( n = 15). Fed‐to‐fasted C max and AUC GMRs were 106.2 (94.3–119.7) ( n = 16) and 109.8 (104.4–115.5) ( n = 15) at 75 mg ( n = 16), and 115.9 (104.3–128.7) and 102.3 (98.0–106.8) at 300 mg ( n = 15). Absolute oral bioavailability at 75 mg ( n = 6) and 300 mg ( n = 6) was 42.5% (36.8%–49.0%) and 55.1% (48.5%–62.5%). The formulations showed similar exposures, supporting the planned manufacturing changes. Camizestrant exhibited moderate bioavailability; exposures were similar under fasted and high‐fat meal conditions, supporting its administration with or without food.
- Open Access
- 19 June 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (8) , 100110
The application of mechanistic absorption, distribution, metabolism and excretion studies and physiologically-based pharmacokinetic modeling in the discovery of the next-generation oral selective estrogen receptor degrader camizestrant to achieve an acceptable human pharmacokinetic profile
- 19 June 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (8) , 100110
Open AccessThe application of mechanistic absorption, distribution, metabolism and excretion studies and physiologically-based pharmacokinetic modeling in the discovery of the next-generation oral selective estrogen receptor degrader camizestrant to achieve an acceptable human pharmacokinetic profile